NYSE:NVS

Energize – A First-of-Its-Kind Program to Increase Access to Renewable Energy for Pharmaceutical Suppliers

Article

The Energize program is a collaboration between 10 global pharmaceutical companies, including Novartis, to engage hundreds of suppliers in bold climate action and decarbonization of the pharmaceutical value chain. The program is a first-of-its-kind effort to leverage the scale of a single industry’s global supply chain in a pre-competitive fashion to drive system level change. Creating life-saving medicines and services requires a lot of energy, much of it being used by the value chain.

Novartis and Medicines for Malaria Venture Report Positive Results for Phase 2b Study of Novel Ganaplacide/Lumefantrine Combination in Children With Malaria

Summary: 
  • Novartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malaria
  • In the Phase 2b study conducted in children less than 12 years of age, ganaplacide/lumefantrine met the primary study objective
  • The positive Phase 2b results for the next generation antimalarial therapy support continued development of the combination
Press Release
  • Novartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malaria
  • In the Phase 2b study conducted in children less than 12 years of age, ganaplacide/lumefantrine met the primary study objective
  • The positive Phase 2b results for the next generation antimalarial therapy support continued development of the combination

Together Against Child Mortality: Novartis and Save the Children Launch Health Project in the Slums of Nairobi

Summary: 
  • Novartis partners with Save the Children to launch first common health project in Kenya
  • First step in the collaboration will focus on providing affordable and effective healthcare to the most deprived children in Kenya
  • Project aims to tackle the problem of under-five child mortality through treatment of malaria, pneumonia, diarrhea and malnutrition
Press Release
  • Novartis partners with Save the Children to launch first common health project in Kenya
  • First step in the collaboration will focus on providing affordable and effective healthcare to the most deprived children in Kenya
  • Project aims to tackle the problem of under-five child mortality through treatment of malaria, pneumonia, diarrhea and malnutrition

Novartis Pledges 10-year Commitment With Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and Other Leading Organizations to Co-create Effective, Measurable Solutions for Health Equity

Press Release
  • Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and others to address root causes of disparities in health and education
  • This collaboration will create actionable solutions to target the systemic racism that drives inequitable health outcomes and work together for health equity progress through greater diversity, equity and inclusion across the research and development ecosystem

Novartis and Hewlett Packard Enterprise Join Forces to Advance Novartis Global Health Efforts

Summary: 
  • Novartis is collaborating with Hewlett Packard Enterprise to accelerate the use of data and digital technologies within its efforts to reimagine global health and improve access to healthcare and medicines.
  • The collaboration will focus on three global health enablers: identifying and integrating complex data sources related to health; advancing the application of artificial intelligence, machine learning and geo-spatial analytics to these data; and expanding access to technology in remote and underserved locations.
  • The first use case for the partnership will seek to develop a disease surveillance solution for dengue fever, initially focusing on India.
Press Release
  • Novartis is collaborating with Hewlett Packard Enterprise to accelerate the use of data and digital technologies within its efforts to reimagine global health and improve access to healthcare and medicines.
  • The collaboration will focus on three global health enablers: identifying and integrating complex data sources related to health; advancing the application of artificial intelligence, machine learning and geo-spatial analytics to these data; and expanding access to technology in remote and underserved locations.
  • The first use case for the partnership will seek to develop a disease surveillance solution for dengue fever, initially focusing on India.

Novartis Inaugurates Innovative Watershed Project in India to Increase Water Availability

Article

Today, on World Water Day, Novartis inaugurated an integrated watershed development project to help address water scarcity in the Telangana region of India, one of the world’s most water-stressed countries.

Novartis and the Bill & Melinda Gates Foundation Collaborate to Discover and Develop an Accessible in Vivo Gene Therapy for Sickle Cell Disease

Summary: 
  • Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
     
  • Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
  • Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa
Press Release
  • Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation
     
  • Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapies
  • Effort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan Africa

Novartis in Society US Report 2020

Reimagining healthcare in challenging times: Novartis in Society US
Article

Novartis is building a leading focused medicines company powered by advanced therapy platforms and data science. At the same time, we are pursuing innovative approaches to making pharmaceuticals more affordable and accessible and strengthening our communities and society. Since 2016, we have published an annual Novartis in Society US Report, which details our goals and activities in support of patients and their families, healthcare providers, the communities where we live and work, and our healthcare system.

Novartis Renews WHO Medicine Donation Pledge With Aim of Ending Leprosy

Summary: 
  • Novartis leprosy medicine donation program with WHO extended to 2025
  • Program has already treated over 7 million patients since 2000
  • New evidence from contact tracing and preventive treatment program shows route to accelerate elimination

Watch the Novartis Leprosy Youtube Video.

Access the Leprosy content on novartis.com.

Visit Novartis Global Health on Twitter and Linkedin.

Press Release
  • Novartis leprosy medicine donation program with WHO extended to 2025
  • Program has already treated over 7 million patients since 2000
  • New evidence from contact tracing and preventive treatment program shows route to accelerate elimination

Watch the Novartis Leprosy Youtube Video.

Access the Leprosy content on novartis.com.

Visit Novartis Global Health on Twitter and Linkedin.

Novartis and GSK Announce Collaboration to Support Scientific Research Into Genetic Diversity in Africa

Summary: 
  • Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients
  • Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years

  • Researchers based at universities, science councils and other public research organizations across Africa are invited to express ‘intent to submit’ by  March 1, 2021

Press Release
  • Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients
  • Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years

  • Researchers based at universities, science councils and other public research organizations across Africa are invited to express ‘intent to submit’ by  March 1, 2021

Pages

Subscribe to NYSE:NVS